Ian Thomas Lund PA

PubMed

• 32 citations
  Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).
  Othman S. Akhtar, Kris Attwood, Ian Lund, Ryan Hare, Francisco J. Hernandez-Ilizaliturri
  Leukemia & Lymphoma. 2019-01-02

Journal Articles

• P831: Novel immunosuppressive myeloid populations in the bone marrow and osteolytic lesions of Multiple Myeloma patients.  
  Hillengass J, Lannes R, Daneshmandi S, MacDonald C, Yan Qi, Choi J, Singh Prashant, Belal A, Alberico Ronald, Lund, I, Schaefer M, Parker Sarah, Munshi Nikhil, Anderso..., Hemasphere, 8/2023
• Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma  
  Shalaby K, Carlson L, Celotto K, Chavel C, Lund I, McCaffrey K, Schaefer M, Dupuis M, Hillengass K, Lee K., J Clin Onc, 6/2023
• P. Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study.  
  Akhtar OS, Groman A, Singh A, Ghione P, Lund I, Hernandez-Ilizaliturri FJ, Torka P, Leuk Lymphoma, 5/2022
• Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of ...  
  Torka P, Akhtar OS, Reddy NM, Baysal BE, Kader A, Groman A, Nichols J, Mavis C, Tario JD, Block AW, Sait SNJ, Ghione P, Sundaram S, Przespolewski ER, Mohr A, Lund I, K..., Cancer, 4/2022
• A Phase 1 Study OF Carfilzomib with Rituximab, Ifosphamide, Carboplatin and Etoposide (C-RICE) in Transplant-eligible Relapsed/refractory Diffuse Large B-Cell Lymphoma.  
  Torka P, Groman A, Wong J, Baysal B, Nichols J, Kader A, Mavis C, Jani Sait S, Block A, Przespolewski E, Mohr A, Lund I, McWhite K, Kostrewa J, DeMarco J, Johnson M, D..., Hematological Oncology, 2021
• Efficacy and safety of Dexamethasone, high dose cytarabine, and carboplatin (DHAC) with and without rituximab (R) as a salvage regimen for relapsed/refractory (R/R) ly...  
  Baron J, Menon M, Hare R, Lund I, Mohr A, Rondeau C, Syta M, Celotto K, Iyer SP, Bhat S, Hernandez-Ilizaliturri F., J Clin Onc, 2016
• Join now to see all

Abstracts/Posters

• Impact of social determinants of health on survival outcomes in Multiple Myeloma patients at a major cancer center.
  Alharbi M, Abdalla E, Bawek S, Forbes C, Lund I, Yu H, Durand B, Hillengass J, Hassan H., ASH 2024
• Effects of Dose reductions of Lenalidomide given as maintenance following autologous stem cell transplant in patients with Multiple Myeloma.
  Lund I, Azad F, Attwood K, George, A, Hillengass, J., ASH 2023